
SK Life Science Seeks FDA Approval for Cenobamate Oral Suspension
The U.S. Food and Drug Administration has accepted for review a New Drug Application for an investigational oral suspension of cenobamate. Designed for adults with focal seizures who struggle to swallow tablets, the new formulation faces a target action date of January 31, 2027, under the Prescription Drug User Fee Act.

























